Neumora Therapeutics, Inc. (NMRA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for brain and centrally mediated diseases using a precision neuroscience approach. The company has no approved products and has not generated revenue from product sales. Its primary pipeline includes navacaprant (Phase 3 for Major Depressive Disorder), NMRA-511 (Phase 1b for agitation in Alzheimer's disease), and NMRA-861 (Phase 1 for schizophrenia).
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(52.7) million | $(58.7) million | $(120.7) million | $(112.4) million |
| Net Loss Per Share | $(0.33) | $(0.37) | $(0.75) | $(0.71) |
| Operating Expenses | $54.0 million | $63.8 million | $125.0 million | $123.9 million |
| R&D Expenses | $38.7 million | $48.6 million | $90.9 million | $94.4 million |
| G&A Expenses | $15.3 million | $15.2 million | $34.1 million | $29.5 million |
| Cash & Equivalents | $124.5 million | $142.1 million | $124.5 million | $150.7 million |
| Marketable Securities | $93.1 million | $165.4 million | $93.1 million | $165.4 million |
| Total Liquidity | $217.6 million | $307.5 million | $217.6 million | $316.1 million |
| Long-Term Debt | $19.5 million | $0 | $19.5 million | $0 |
Material Changes vs. Prior Period
- Debt Financing: In May 2025, the company entered into a loan agreement with K2 HealthVentures LLC for up to $125.0 million. The first tranche of $20.0 million was funded, resulting in $19.5 million of long-term debt on the balance sheet (net of issuance costs).
- Expense Reduction: Q2 2025 R&D expenses decreased by $9.9 million (20%) compared to Q2 2024, primarily due to reduced navacaprant program costs and lower personnel-related costs (including a reduction in stock-based compensation).
- Interest Income Decline: Net interest income dropped significantly to $1.8 million in Q2 2025 from $5.3 million in Q2 2024, driven by lower balances in cash and marketable securities.
- Stock-Based Compensation: Total stock-based compensation decreased to $7.2 million in Q2 2025 from $12.8 million in Q2 2024, reflecting lower headcount and the absence of one-time modification expenses incurred in the prior year.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($217.6 million) are sufficient to fund operations for at least the next 12 months. However, the company expects to incur additional losses and will require further capital to complete development and commercialization.
- Clinical Updates: The company noted in the risk factors that the KOASTAL-1 study for navacaprant did not demonstrate a statistically significant improvement on the primary endpoint (MADRS total score) or key secondary endpoint (SHAPS scale) as of January 2025.
- Legal Proceedings: A putative securities class action lawsuit was filed in February 2025 alleging violations of the Securities Act related to the 2023 IPO. The company intends to move to dismiss.
- Contingent Consideration: The company has significant potential future obligations related to acquisitions (BlackThorn, Vanderbilt, Amgen) totaling hundreds of millions in potential milestone payments, which could be settled in cash or stock.
- Stock Price Compliance: The company regained compliance with Nasdaq's $1.00 minimum bid price requirement in July 2025 after previously receiving a deficiency notice.
Investor Verification Checklist
- Runway Analysis: Verify the burn rate against the $217.6 million liquidity position to confirm the 12-month runway estimate.
- Debt Covenants: Review the specific liquidity covenants and interest rate terms (variable rate, minimum 10.45%) of the new K2 HealthVentures term loan.
- Navacaprant Strategy: Assess management's plan for the navacaprant program following the negative topline data from the KOASTAL-1 study mentioned in the risk factors.
- Contingent Liabilities: Evaluate the probability and potential dilution impact of the substantial milestone payments owed to BlackThorn and Vanderbilt.
- Legal Exposure: Monitor the status of the securities class action lawsuit filed in February 2025.